Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.

Bobu, Amelian Madalin et al.·Journal of clinical medicine·2025·
RPEP-101862025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.
Published In:
Journal of clinical medicine, 14(10) (2025)
Database ID:
RPEP-10186

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10186·https://rethinkpeptides.com/research/RPEP-10186

APA

Bobu, Amelian Madalin; Turliuc, Serban; Cucu, Andrei Ionut; Onofriescu, Alina; Dascalu, Cristina Gena; Costea, Claudia Florida; Patrascanu, Emilia; Morosan, Anca Petruta; Haisan, Anca; Filip, Carmen Nicoleta; Covali, Roxana; Buzduga, Catalin Mihai; Botnariu, Gina; Enache, Irina Iuliana Costache. (2025). Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.. Journal of clinical medicine, 14(10). https://doi.org/10.3390/jcm14103536

MLA

Bobu, Amelian Madalin, et al. "Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14103536

RethinkPeptides

RethinkPeptides Research Database. "Dulaglutide 1.5 mg Significantly Improves Glycemic Control a..." RPEP-10186. Retrieved from https://rethinkpeptides.com/research/bobu-2025-dulaglutide-15-mg-significantly

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.